IP Library Granted Patent US 6,860,851
Granted Patent B2
US 6,860,851 · App. 10/306,872 · Granted Mar 1, 2005

Vulnerable plaque diagnosis and treatment

View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 6,860,851
App. No.
10/306,872
Granted
Mar 1, 2005
Kind
B2
Abstract

Vulnerable plaque is identified through a diagnostic method by identifying pathologic markers such as C-reactive proteins or pH change generated by the pathologic site. First and second detectors are advanced through a blood vessel with each of the detectors selected to detect the pathological marker. The detectors are spaced apart while seeking the marker. Differential concentration of the pathological marker as measured by the first and second detectors indicates a presence of the pathological site in proximity to at least one of the detectors.

Claims (13)

1. A diagnostic method for identifying a pathologic site in a blood vessel, of a patient's vasculature wherein said pathologic site is characterized by a generation of a pathologic marker, said method comprising:

advancing a first detector and a second detector into said vasculature with each of said first and second detectors selected to detect an intensity of said marker, said detectors being arranged to avoid contact with a wall of the vasculature;

spacing said first and second detectors apart while said detectors are seeking detection of said marker;

advancing at least one of said detectors through said vessel with each of said detectors measuring an intensity of said marker at a location in said vasculature of each of said detectors; and

comparing an intensity of said marker as measured by each of said detectors and noting an increase in intensity of said marker as measured by said at least one of said detectors relative to an intensity of said marker as measured by the other of said detectors;

wherein a differential of intensity of said marker between said first and second detectors indicates a presence of said pathologic site in proximity to said at least one of the detectors and with said differential compensating for a systemic presence of said marker.

2. A method according to claim 1 comprising narrowing a spacing between said first and second detectors after said indication of said presence of said pathologic site to more narrowly focus on said pathologic site.

3. A method according to claim 1 wherein said pathologic site is a vulnerable plaque.

4. A method according to claim 1 wherein said pathologic marker is a C-reactive protein.

5. A method according to claim 1 wherein said pathologic marker is a hydrogen ion concentration (pH).

6. A method according to claim 1 wherein said pathologic marker is an increase in temperature.

7. A method according to claim 1 wherein said pathologic marker is a localized inflammation marker.

8. A method according to claim 1 wherein each of said first and second detectors is placed in said vessel.

Assignments (5)
CHANGE OF NAME Recorded Mar 30, 2018
From: ENTEROMEDICS INC.
To: RESHAPE LIFESCIENCES INC.
Reel/Frame 045949/0495 →
MERGER Recorded Jan 6, 2010
From: ENTEROMEDICS INC., A MINNESOTA CORPORATION
To: ENTEROMEDICS INC., A DELAWARE CORPORATION
Reel/Frame 023731/0752 →
MERGER Recorded Jan 26, 2004
From: ALPHA MEDICAL, INC.
To: BETA MEDICAL, INC.
Reel/Frame 014914/0917 →
CHANGE OF NAME Recorded Jan 26, 2004
From: BETA MEDICAL, INC.
To: ENTEROMEDICS INC.
Reel/Frame 014916/0339 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Mar 18, 2003
From: KNUDSON, MARK B.; CONRAD, TIMOTHY R.; TWEDEN, KATHERINE S.
To: ALPHA MEDICAL, INC.
Reel/Frame 013859/0418 →